BRPI0715126B8 - métodos para avaliação do risco de intervenções cardíacas e usos à base de gdf-15 - Google Patents
métodos para avaliação do risco de intervenções cardíacas e usos à base de gdf-15Info
- Publication number
- BRPI0715126B8 BRPI0715126B8 BRPI0715126A BRPI0715126A BRPI0715126B8 BR PI0715126 B8 BRPI0715126 B8 BR PI0715126B8 BR PI0715126 A BRPI0715126 A BR PI0715126A BR PI0715126 A BRPI0715126 A BR PI0715126A BR PI0715126 B8 BRPI0715126 B8 BR PI0715126B8
- Authority
- BR
- Brazil
- Prior art keywords
- gdf
- subject
- methods
- risk assessment
- present
- Prior art date
Links
- 230000000747 cardiac effect Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 title abstract 3
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 title abstract 3
- 238000012502 risk assessment Methods 0.000 title 1
- 108020001621 Natriuretic Peptide Proteins 0.000 abstract 1
- 102000004571 Natriuretic peptide Human genes 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000007211 cardiovascular event Effects 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 239000000692 natriuretic peptide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Abstract
meios e métodos para avaliação do risco de intervenções cardíacas baseados em gdf-15. a presente invenção se refere a um método de identificação de um sujeito suscetível a uma intervenção cardíaca com base na determinação de gdf-15 em uma amostra do sujeito necessitado de uma intervenção cardíaca. além disso, a presente invenção se refere a um método para predizer o risco de mortalidade ou de um evento cardiovascular agudo adicional para um sujeito que sofra de uma complicação cardiovascular com base na determinação de gdf-15 e de um peptídeo natriurético e/ou uma troponina cardíaca em uma amostra do dito sujeito. também são englobados pela presente invenção dispositivos e kits para realizar os métodos acima mencionados.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06118464A EP1884777A1 (en) | 2006-08-04 | 2006-08-04 | Means and methods for assessing the risk of cardiac interventions based on GDF-15 |
EP06118464.4 | 2006-08-04 | ||
EP06121413.6 | 2006-09-28 | ||
EP06121413 | 2006-09-28 | ||
EP07108854.6 | 2007-05-24 | ||
EP07108854 | 2007-05-24 | ||
PCT/EP2007/058007 WO2008015254A2 (en) | 2006-08-04 | 2007-08-02 | Means and methods for assessing the risk of cardiac interventions based on gdf-15 |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0715126A2 BRPI0715126A2 (pt) | 2013-06-04 |
BRPI0715126B1 BRPI0715126B1 (pt) | 2018-05-22 |
BRPI0715126B8 true BRPI0715126B8 (pt) | 2021-07-27 |
Family
ID=38596870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0715126A BRPI0715126B8 (pt) | 2006-08-04 | 2007-08-02 | métodos para avaliação do risco de intervenções cardíacas e usos à base de gdf-15 |
Country Status (12)
Country | Link |
---|---|
US (3) | US8951742B2 (pt) |
EP (2) | EP2315034A3 (pt) |
JP (1) | JP5309026B2 (pt) |
KR (1) | KR101245877B1 (pt) |
CN (1) | CN106018820B (pt) |
AT (1) | ATE511656T1 (pt) |
AU (1) | AU2007280413B2 (pt) |
BR (1) | BRPI0715126B8 (pt) |
CA (1) | CA2660691C (pt) |
HK (1) | HK1136627A1 (pt) |
MX (1) | MX2009000914A (pt) |
WO (1) | WO2008015254A2 (pt) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE537454T1 (de) * | 2007-05-24 | 2011-12-15 | Hoffmann La Roche | Verfahren zum beurteilen von herzinsuffizienz bei patienten mit vorhofflimmern mittels gdf-15 |
JP5198565B2 (ja) * | 2007-08-30 | 2013-05-15 | エフ.ホフマン−ラ ロシュ アーゲー | 心疾患に関連する又は関連しないgdf−15の上昇の区別のための手段及び方法 |
JP2011501112A (ja) | 2007-10-10 | 2011-01-06 | エフ.ホフマン−ラ ロシュ アーゲー | 心筋梗塞のモニタリング及びその治療のための手段及び方法 |
EP2103943A1 (en) | 2008-03-20 | 2009-09-23 | F. Hoffman-la Roche AG | GDF-15 for assessing a cardiovascular risk with respect to the administration of antiinflammatory drugs |
JP5524182B2 (ja) * | 2008-04-30 | 2014-06-18 | エフ.ホフマン−ラ ロシュ アーゲー | 心不全の評価におけるsfrp−3の使用 |
WO2010007041A1 (en) * | 2008-07-14 | 2010-01-21 | Roche Diagnostics Gmbh | Multimarker panel for diagnosing, monitoring and selecting the therapy for patients with heart failure |
ES2647461T3 (es) * | 2009-12-18 | 2017-12-21 | F. Hoffmann-La Roche Ag | GDF-15 y/o troponina T para predecir insuficiencia renal en pacientes con cirugía cardíaca |
EP2388594A1 (en) * | 2010-05-17 | 2011-11-23 | Roche Diagnostics GmbH | GDF-15 based means and methods for survival and recovery prediction in acute inflammation |
US8315812B2 (en) | 2010-08-12 | 2012-11-20 | Heartflow, Inc. | Method and system for patient-specific modeling of blood flow |
CA2807213C (en) | 2010-08-26 | 2022-06-28 | F. Hoffman-La Roche Ag | Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure |
EP2646822B1 (en) * | 2010-11-29 | 2017-11-01 | Alere San Diego, Inc. | Methods for diagnosis and risk prediction in heart failure |
WO2013022760A1 (en) * | 2011-08-05 | 2013-02-14 | Alere San Diego, Inc. | Methods and compositions for monitoring heart failure |
CA2846285C (en) | 2011-10-17 | 2019-09-24 | F. Hoffmann-La Roche Ag | Troponin and bnp based diagnosis of risk patients and cause of stroke |
WO2013148117A1 (en) | 2012-03-27 | 2013-10-03 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
EP3434260A1 (en) * | 2012-05-18 | 2019-01-30 | Critical Care Diagnostics, Inc. | Methods for treating or predicting risk of ventricular tachyarrhythmia event |
US9002769B2 (en) * | 2012-07-03 | 2015-04-07 | Siemens Aktiengesellschaft | Method and system for supporting a clinical diagnosis |
EP2730923A1 (en) | 2012-11-09 | 2014-05-14 | Roche Diagniostics GmbH | NTproBNP and cTnT based therapy guidance in heart failure |
CN113759128A (zh) | 2012-12-04 | 2021-12-07 | 霍夫曼-拉罗奇有限公司 | 心力衰竭疗法的选择中的生物标记物 |
US9175076B2 (en) | 2012-12-21 | 2015-11-03 | Aveo Pharmaceuticals, Inc. | Anti-GDF15 antibodies |
DE102013100367A1 (de) | 2013-01-15 | 2014-07-17 | Sick Ag | Entfernungsmessender optoelektronischer Sensor und Verfahren zur Abstandsbestimmung von Objekten |
BR112015018104A2 (pt) | 2013-01-30 | 2017-11-21 | Ngm Biopharmaceuticals Inc | polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
EP3441768A3 (en) | 2013-08-26 | 2019-03-20 | Roche Diagnostics GmbH | Marker for statin treatment stratification in heart failure |
EP3470848A3 (en) | 2014-01-28 | 2019-05-22 | Roche Diagnostics GmbH | Biomarkers for risk assessment and treatment monitoring in heart failure patients guided by natriuretic peptides |
CN106413740A (zh) * | 2014-06-13 | 2017-02-15 | 诺华股份有限公司 | 用于降低gdf‑15的serelaxin应用 |
US20170137505A1 (en) * | 2014-06-20 | 2017-05-18 | Aveo Pharmaceuticals, Inc. | Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator |
WO2016018931A1 (en) | 2014-07-30 | 2016-02-04 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
PE20171058A1 (es) | 2014-10-31 | 2017-07-21 | Ngm Biopharmaceuticals Inc | Composiciones y metodos de uso para tratar trastornos metabolicos |
US11604194B2 (en) | 2016-02-29 | 2023-03-14 | Public University Corporation Yokohama City University | Method for detecting castration-resistant prostate cancer and detection reagent |
AU2017241161B2 (en) | 2016-03-31 | 2022-05-26 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
US10279712B2 (en) | 2016-07-14 | 2019-05-07 | Bae Industries, Inc. | Rear row seat latch assembly with power and manual driven variants |
US10195962B2 (en) | 2016-07-14 | 2019-02-05 | Bae Industries, Inc. | Power seat assembly with spring loaded seatback dump and motor driven design rewind and reset functionality |
JP7127422B2 (ja) | 2017-08-30 | 2022-08-30 | 東ソー株式会社 | 癌を検出する方法及び検出試薬 |
EP3943946A1 (en) | 2020-07-20 | 2022-01-26 | F. Hoffmann-La Roche AG | Gdf-15 for predicting the disease severity of a patient with covid-19 |
GB2621544A (en) * | 2022-07-07 | 2024-02-21 | Biohabit Ltd | Methods of detecting a disease or condition |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
GB9211686D0 (en) | 1992-06-03 | 1992-07-15 | Medisinsk Innovation A S | Chemical compounds |
DK0808172T3 (da) * | 1995-02-10 | 2003-10-20 | Searle & Co | Kombinationer af angiotensinkonverterende enzyminhibitor og bivirkningsreducerende mængde af aldesteronantagonist |
US6248869B1 (en) * | 1997-05-29 | 2001-06-19 | Medical Analysis Systems, Inc. | Troponin I forms and use of the same |
WO1999006445A1 (en) | 1997-07-31 | 1999-02-11 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-15 |
AU5067100A (en) * | 1999-05-17 | 2000-12-05 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh | Neuroprotective properties of gdf-15, a novel member of the tgf-beta superfamily |
SE0000363L (sv) * | 2000-02-04 | 2001-08-05 | Zoucas Kirurgkonsult Ab | Belagd medicinsk anordning |
ATE470863T1 (de) | 2000-04-20 | 2010-06-15 | St Vincents Hosp Sydney | Diagnostischer assay mit makrophagenhemmendem zytokin-1 (mic-1) |
WO2002059373A2 (en) | 2001-01-23 | 2002-08-01 | Irm, Llc | Genes overexpressed in prostate disorders as diagnostic and therapeutic targets |
US7524635B2 (en) * | 2003-04-17 | 2009-04-28 | Biosite Incorporated | Methods and compositions for measuring natriuretic peptides and uses thereof |
US7632647B2 (en) | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
ATE458199T1 (de) | 2001-05-04 | 2010-03-15 | Biosite Inc | Diagnostische marker der akuten koronaren syndrome und ihre verwendungen |
CA2445991A1 (en) * | 2001-06-05 | 2002-12-12 | Genomics, Ltd. | Compositions and methods for the detection of biomarkers associated with cardiovascular disease |
WO2003039601A1 (en) * | 2001-11-07 | 2003-05-15 | Imcor Pharmaceutical Company | Methods for vascular imaging using nanoparticulate contrast agents |
MXPA03004105A (es) * | 2002-05-14 | 2004-10-15 | Hoffmann La Roche | Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores. |
US7157235B2 (en) * | 2002-06-17 | 2007-01-02 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
US20040096919A1 (en) * | 2002-11-18 | 2004-05-20 | Michelle Davey | Polyclonal-monoclonal ELISA assay for detecting N-terminus proBNP |
EP1587955A4 (en) * | 2002-12-24 | 2007-03-14 | Biosite Inc | DIFFERENTIAL DIAGNOSTIC MARKERS AND METHODS OF USE |
US20040215240A1 (en) * | 2003-04-11 | 2004-10-28 | Lovett Eric G. | Reconfigurable subcutaneous cardiac device |
GB2403533A (en) * | 2003-06-30 | 2005-01-05 | Orion Corp | Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof |
EP1577673B1 (en) * | 2004-03-15 | 2008-07-30 | F. Hoffmann-La Roche Ag | The use of BNP-type peptides and ANP-type peptides for assessing the risk of suffering from a cardiovascular complication as a consequence of volume overload |
EP2774620A1 (en) * | 2004-04-13 | 2014-09-10 | St Vincent's Hospital Sydney Limited | Method for modulating weight loss |
WO2005113585A2 (en) | 2004-05-20 | 2005-12-01 | Acceleron Pharma Inc. | Modified tgf-beta superfamily polypeptides |
WO2005124364A1 (en) * | 2004-06-15 | 2005-12-29 | F. Hoffmann-La Roche Ag | The use of cardiac hormones for diagnosing the risk of suffering from a cardiovascular complication as a consequence of cardiotoxic medication |
-
2007
- 2007-08-02 MX MX2009000914A patent/MX2009000914A/es active IP Right Grant
- 2007-08-02 KR KR1020097002246A patent/KR101245877B1/ko active IP Right Grant
- 2007-08-02 AU AU2007280413A patent/AU2007280413B2/en active Active
- 2007-08-02 BR BRPI0715126A patent/BRPI0715126B8/pt not_active IP Right Cessation
- 2007-08-02 EP EP11150888A patent/EP2315034A3/en not_active Withdrawn
- 2007-08-02 AT AT07802468T patent/ATE511656T1/de active
- 2007-08-02 CN CN201610159375.1A patent/CN106018820B/zh active Active
- 2007-08-02 WO PCT/EP2007/058007 patent/WO2008015254A2/en active Search and Examination
- 2007-08-02 JP JP2009522281A patent/JP5309026B2/ja active Active
- 2007-08-02 EP EP07802468A patent/EP2047275B1/en active Active
- 2007-08-02 CA CA2660691A patent/CA2660691C/en active Active
-
2009
- 2009-02-02 US US12/363,932 patent/US8951742B2/en active Active
-
2010
- 2010-02-24 HK HK10101926.5A patent/HK1136627A1/zh unknown
-
2015
- 2015-02-09 US US14/617,927 patent/US20150362511A1/en not_active Abandoned
-
2019
- 2019-09-06 US US16/562,894 patent/US11199552B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US8951742B2 (en) | 2015-02-10 |
KR20090047451A (ko) | 2009-05-12 |
US20150362511A1 (en) | 2015-12-17 |
US11199552B2 (en) | 2021-12-14 |
US20200081020A1 (en) | 2020-03-12 |
CN106018820A (zh) | 2016-10-12 |
MX2009000914A (es) | 2009-06-18 |
EP2315034A2 (en) | 2011-04-27 |
WO2008015254A3 (en) | 2008-06-05 |
BRPI0715126A2 (pt) | 2013-06-04 |
BRPI0715126B1 (pt) | 2018-05-22 |
KR101245877B1 (ko) | 2013-03-20 |
CA2660691A1 (en) | 2008-02-07 |
HK1136627A1 (zh) | 2010-07-02 |
EP2315034A3 (en) | 2011-08-17 |
EP2047275A2 (en) | 2009-04-15 |
AU2007280413A1 (en) | 2008-02-07 |
JP2009545735A (ja) | 2009-12-24 |
CN106018820B (zh) | 2018-04-27 |
EP2047275B1 (en) | 2011-06-01 |
CA2660691C (en) | 2020-01-14 |
WO2008015254A2 (en) | 2008-02-07 |
US20110065204A1 (en) | 2011-03-17 |
ATE511656T1 (de) | 2011-06-15 |
JP5309026B2 (ja) | 2013-10-09 |
AU2007280413B2 (en) | 2010-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0715126B8 (pt) | métodos para avaliação do risco de intervenções cardíacas e usos à base de gdf-15 | |
ATE433124T1 (de) | System und verfahren zum analysieren von radarinformationen | |
WO2008089994A8 (en) | Use of igfbp-7 in the assessment of heart failure | |
WO2008131224A3 (en) | Diabetes-related biomarkers and methods of use thereof | |
ATE482398T1 (de) | Verfahren zur stratifizierung von herzinsuffizienz | |
DK2341344T3 (da) | Fremgangsmåde til diagnosticering af en polycystisk nyresygdom | |
ATE541054T1 (de) | Bio-barcode erkennung für zielmoleküle | |
BRPI0716944A2 (pt) | biomarcadores de modulaÇço alvo, eficÁcia, diagnàstico, e/ou prognàstico para inibidores de raf | |
ATE535805T1 (de) | Verfahren zur erkennung von autoantikörpern zur diagnostizierung und charakterisierung von erkrankungen | |
DE602007013524D1 (de) | Erkennung und vorhersage von frühgeburten | |
EA201370063A1 (ru) | Фосфолипидом рака | |
DE602006020904D1 (de) | Verfahren zum testen von antigen | |
DE602006012456D1 (de) | Kühlgerät, steuerverfahren für das kühlgerät und verfahren zur bestimmung von anomalien | |
BRPI0912136A2 (pt) | métodos para diagnosticar proliferação peroxissomal aumentada e para identificar uma substância para tratar proliferação peroxissomal aumentada, e, uso de pelo menos cinco analitos e de meios para a determinação de pelo menos cinco analitos | |
ATE529533T1 (de) | Verfahren zum nachweis von analyten in einer probe | |
WO2009141352A3 (en) | Risk analysis in patients with and without metabolic syndrome | |
WO2008131261A3 (en) | Peptide biomarkers of cardiovascular disease | |
WO2008145701A9 (en) | Method for predicting the outcome of a critically ill patient | |
BR112012024175A2 (pt) | hbf e a1m como marcadores de estágio precoce para preeclampsia | |
DE602007004570D1 (de) | Verwendung von Nogo-C bei der Beurteilung von Herzversagen | |
DE602006001190D1 (de) | Positionierungsgerät, Steuerverfahren für das Positionierungsgerät, Steuerprogramm für das Positionierungsgerät und computerlesbares Aufzeichnungsmedium zur Aufzeichnung des Steuerprogramms für das Positionierungsgerät | |
WO2010043393A8 (en) | Use of biglycan in the assessment of heart failure | |
BRPI0906410A2 (pt) | Análise e método para a avaliação de respondedores e de não respondedores à modulação de célula nk através da terapia de imunoglobulina | |
DK1991875T3 (da) | Test til påvisning af patologiske prioner | |
WO2009078806A3 (en) | Skeletal muscle proteome, muscle function and physical performance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/08/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 17A ANUIDADE. |